Navigation Links
Enterome Announces Collaboration with Johnson & Johnson Innovation Focused on the Discovery of Novel Targets and Therapeutics for Crohn's Disease
Date:1/7/2016

PARIS and BOSTON, January 7, 2016 /PRNewswire/ --

Enterome Bioscience SA ("Enterome"), a pioneer in the development of therapeutic solutions based on the gut microbiome, announces that it has entered into a collaborative research agreement with Janssen Biotech, Inc. (Janssen Biotech), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the French National Institute for Agriculture Research (INRA).

The agreement, facilitated by Johnson & Johnson Innovation, is focused on the discovery of novel targets and bioactive molecules from the gut microbiome for the potential development of therapeutic solutions to Crohn's disease. 

Enterome has already identified bacterial strains, genes and products with immunomodulatory and anti-inflammatory properties by combining its own advanced proprietary metagenomics tools and screening technologies. The collaboration aims to advance the characterization and therapeutic validation of these bacterial products, increase knowledge of the regulation of immunity and gut homeostasis, and potentially lead to the development of new therapeutic solutions for Crohn's disease.

Under the terms of the agreement, Enterome is eligible to receive an upfront payment plus R&D funding from Janssen. Janssen receives an option to take an exclusive license to further develop and commercialize promising candidates that may arise from the collaboration. The Janssen Human Microbiome Institute will also join the collaboration to help accelerate the translation of microbiome science into therapeutic solutions in the area of Crohn's disease.

The collaboration is based on initial findings by INRA showing that some commensal (symbiotic) bacteria elicit anti-inflammatory effects in the human gut.  

Pierre Belichard, CEO of Enterome commented, "Enterome is proud of its leading position in discovering and developing microbiome-derived therapeutics for Crohn's disease, and we look forward to advancing through collaborations that continue to reflect positively on our strong recognition from the pharmaceutical industry."

About Enterome 

Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Disease (IBD), cancer and metabolic diseases.

Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. This technology leadership allows Enterome to open up the new field of therapeutic target discovery in the microbiome in order to address significant unmet medical needs.

The Company was established in 2012 in Paris, France to develop the discoveries made by the INRA metagenomic platform. The Company has raised a total of €17.5 million from leading venture capital investors (Seventure Partners, Lundbeckfond Ventures & Omnes Capital) and two strategic investors (Shire & INRA transfer).

Additional information about Enterome is available through its website:  http://www.enterome.com


'/>"/>
SOURCE Enterome Bioscience
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. EnteroMedics to Host Second Quarter 2014 Financial Results and Business Update Conference Call
2. EnteroMedics to Participate in Canaccord Genuity 34th Annual Growth Conference
3. EnteroMedics Reports Second Quarter 2014 Financial Results
4. Health Care Equipment Equities under the Scanner - Medtronic, Abbott Laboratories, Stryker, Zeltiq Aesthetics, and EnteroMedics
5. Treatment of Type 2 Diabetes Mellitus added to EnteroMedics CE Mark for Obesity
6. EnteroMedics to Host Fourth Quarter 2014 Financial Results and Commercialization Update Conference Call
7. EnteroMedics Reports Fourth Quarter 2014 Financial Results
8. EnteroMedics to Present at Upcoming Investor Conferences
9. EnteroMedics Announces Partnership with American HealthCare Lending to Support Patient Access and Enhance Affordability of vBloc Therapy
10. EnteroMedics Announces Update on vBloc Therapy Trained Centers and Physicians
11. EnteroMedics Reports First Quarter 2015 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... 28, 2017 The global market ... with the top three companies, namely Shimadzu Corporation, Thermo ... significant 49% of the overall market in 2015, observes ... landscape is intensely competitive and has few players, most ... These factors have restricted the entry of new players ...
(Date:3/28/2017)... TEL AVIV, Israel , March 28, 2017 ... . This new business entity, Emosis Ltd, headquartered in ... and development of novel assays complementing the mother company existing technology ... support commercialization and sales development of Emosis kits. ... This strategic move starts building Emosis ...
(Date:3/28/2017)... 28, 2017  CASI Pharmaceuticals, Inc. (Nasdaq: CASI), ... cancer and other unmet medical needs, announced today ... Cancer Research annual meeting.  The first poster to ... "Evaluation of ENMD-2076 in Combination with Anti-PD1 in ... to be presented on April 4 is entitled ...
Breaking Medicine Technology:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in ... has a lot to offer to the discussion of dealing with excess skin oil. ... there are many home remedies that can help remove the oily shine while keeping the ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... treatment, with or without a referral. Sleep apnea is often left untreated because patients ... morning headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of ...
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
Breaking Medicine News(10 mins):